Pancreatitis Risk
Pancreatitis has been a regulatory concern for GLP-1 receptor agonists as a class since early post-marketing observations. The FDA label for tirzepatide includes a warning about pancreatitis risk. However, systematic review evidence for tirzepatide specifically does not show a statistically significant increase in pancreatitis vs comparators.
A meta-analysis by Zeng et al. (Front Endocrinol 2023, PMID 37908750; 9 trials, 9871 participants) found RR 1.46 (95% CI 0.59–3.61; p=0.436) for pancreatitis — not statistically significant. A larger meta-analysis by Goyal et al. (2024, PMID 39720158; 17 trials, 14,645 participants) confirmed identical risks of pancreatitis to placebo across all tirzepatide doses (5mg: RR 2.04, CI 0.27–15.69, p=0.49; 10mg: RR 0.63, CI 0.08–5.12, p=0.67; 15mg: RR 1.26, CI 0.36–4.98, p=0.72). However, tirzepatide at all doses caused greater increases in pancreatic amylase and lipase than placebo — a laboratory finding that does not translate to clinical pancreatitis in these trials but is a signal of pancreatic stress worth monitoring.
Ontology Pancreatitis Risk [warns_about] Tirzepatide Pancreatitis Risk [relates] GLP-1 Receptor Agonism
Numbers
- Pancreatitis RR: 1.46 (95% CI 0.59–3.61) vs all comparators — NOT significant (9 trials, 9871 participants)
- Pancreatitis per dose vs placebo: RR 2.04/0.63/1.26 — none significant (17 trials, 14,645 participants)
- Lipase elevation: Greater with tirzepatide vs placebo and insulin; comparable to GLP-1 RAs
- Absolute rate: ≤1% across all doses
Practical Interpretation
- Risk level: Not significantly elevated in RCT populations; evidence reassuring but based on 12–72 week trials
- Severity: Acute pancreatitis can be severe or fatal — any case is clinically important
- Monitoring: FDA label recommends promptly discontinuing if pancreatitis suspected; do not restart
Connections
- Tirzepatide — warns_about
- Gallbladder Disease — relates (gallstone-induced pancreatitis pathway)